This study also elucidated the regulatory network of LINC00963/miR-320a/XBP1 and its biological function in tumor development, suggesting that both LINC00963 and miR-320a could be potential therapeutic targets for the molecular targeted therapy of DLBCL. The gene discussed is LINC00963; the disease is diffuse large B-cell lymphoma.